High-throughput screening campaign identified a potential small molecule rxfp3/4 agonist

4Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Relaxin/insulin-like family peptide receptor 3 (RXFP3) belongs to class A G protein-coupled receptor family. RXFP3 and its endogenous ligand relaxin-3 are mainly expressed in the brain with important roles in the regulation of appetite, energy metabolism, endocrine homeostasis and emotional processing. It is therefore implicated as a potential target for treatment of various central nervous system diseases. Since selective agonists of RXFP3 are restricted to relaxin-3 and its analogs, we conducted a high-throughput screening campaign against 32,021 synthetic and natural product-derived compounds using a cyclic adenosine monophosphate (cAMP) measurement-based method. Only one compound, WNN0109-C011, was identified following primary screening, secondary screening and dose-response studies. Although displayed agonistic effect in cells overexpressing the human RXFP3, it also showed cross-reactivity with the human RXFP4. This hit compound may provide not only a chemical probe to investigate the function of RXFP3/4, but also a novel scaffold for the development of RXFP3/4 agonists.

Cite

CITATION STYLE

APA

Lin, G., Feng, Y., Cai, X., Zhou, C., Shao, L., Chen, Y., … Wang, M. W. (2021). High-throughput screening campaign identified a potential small molecule rxfp3/4 agonist. Molecules, 26(24). https://doi.org/10.3390/molecules26247511

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free